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Abstract 
Nucleoside diphosphate kinases (NDPKs/NDK/NME) are a multifunctional class of proteins conserved 
throughout evolution. Whilst many of the functions of NDPKs have been identified as intracellular, 
extracellular eukaryotic and prokaryotic NDPK proteins are also detected in multiple systems and 
have been implicated in both normal physiology and disease. This review provides an overview of 
where the field stands on our developing understanding of how NDPK proteins get out of cells, the 
physiological role of extracellular NDPKs, and how extracellular NDPKs may signal to cells. We will 
also discuss some of the unanswered questions, the ‘known-unknowns’ that particularly warrant 
further investigation.  
Introduction 
The nucleoside diphosphate (NDP) kinase (NDK/NDPK/NME) protein family are amongst the most 
evolutionarily conserved proteins from prokaryotes through to complex multicellular eukaryotes [1]. 
NDPKs are small (11-20 KDa) proteins that typically form multimers of dimers as either hexamers or 
tetramers. In eukaryotes [2, 3], NDPKS mostly form hexamers however some NDPKs from 
prokaryotes and eukaryotes form tetramers, e.g. rat [4] and Silk worm (Bombyx  mori) [5]. NDPKs are 
multifunctional proteins with activities including; catalysing phosphorylation of NDPs to nucleoside 
triphosphates (NTPs) via a phosphohistidine intermediate, binding DNA and regulating transcription 
of c-myc and other genes, cleaving DNA, and possessing histidine protein kinase activity (reviewed in 
[6]). Whilst most of the activities described for NDPK proteins are intracellular, NDPK are also 
released/exported from prokaryotic and eukaryotic cells [7]. Because of the absence of functional 
motifs common to secreted proteins in either prokaryotes or eukaryotes, the physiological relevance 
of these extracellular NDPKs (eNDPKs) has been questioned, with some believing that extracellular 
accumulation is a secondary phenomenon of release following cellular damage. In this brief review 
we consider the evidence that eNDPKs have important roles during malignant and infectious 
diseases and identify some areas for future investigation.  
Prokaryotic eNDPKs 
The function and benefit of secreted NDPKs for free living environmental bacteria was largely 
unstudied until recently and requires to be addressed. As is often the case, studies have focused on 
human commensal and pathogenic bacteria. For example, Mycobacterium tuberculosis is believed to 
exploit secreted NDPK in at least two ways. First by modulating macrophage apoptosis as part of an 
immune avoidance strategy and second, when internalised within macrophages, diminishing free-
radical production thereby avoiding intracellular killing [8-10].   
The most extensively studied system in the context of bacterial NDPK mediated-host modification is 
Porphyromanas gingivalis, a Gram-negative anaerobic bacterium associated with chronic 
periodontitis. Like M. tuberculosis, P. gingivalis is also able to survive within host cells and laboratory 
based studies at least indicate that P. gingivalis NDPK is released from primary infected gingival 
epithelial cells in which the bacterium is resident [11].  This extracellular translocation of P. gingivalis 
NDPK occurs in the absence of overt damage to the host cell membranes or host cell death [11]. The 
basis of P. gingivalis eNDPK then acting as a virulence factor includes (i) modulation of host cell 
extracellular ATP (eATP) concentrations resulting in (ii) reduction of host cell eATP/P2X7 signalling 
pathways including reduced NLRP3 inflammasome activation [12-14]. Importantly, a recent study 
has identified that NDPK released from intracellular P. gingivalis localises predominantly to the 
perinuclear area of infected cells but, upon activation of the host cell by eATP, mobilises to the cell 
periphery in preparation for translocation to the extracellular space [11]. This observation therefore 
suggests that the release of P. gingivalis NDPK from its host cell is an orchestrated combined host-
pathogen response to eATP that results in the depletion of eATP via the catalytic action of the 
released NDPK protein [15, 16].  
 
Eukaryotic eNDPKs 
Extracellular NDPKs are also detected across Eukaryota. One study identified that NDPK from 
Leishmania amazonensis spontaneously accumulates extracellularly in culture [17]. This is a highly 
selective process unaccompanied by co-release of any other known cytosolic proteins and 
independent of L. amazonensis damage [17]. As shown for both M. tuberculosis and P. gingivalis 
NDPKs, the NDPK from L. amazonensis diminished macrophage killing in response to eATP [17]. 
Together these observations provide a collective paradigm where intracellular prokaryote and 
eukaryote pathogens can propagate their survival and dispersal by limiting their host cell’s death in 
response to local elevation of eATP, arising as a consequence of the inflammatory response to the 
infection these organisms are mounting [12, 17, 18]. Philosophically this concept has implications for 
our understanding of the co-evolution of host and parasite. It is reasonable to assume that the re-
localisation of foreign NDPK within the host cell and its subsequent translocation to the extracellular 
space will require pathogen-mediated exploitation of host cell mechanisms.  
Drosophila NDPK was first identified in a genetic approach in which developmental mutants were 
identified as having abnormal wing disks [19-21]. For this reason, the Drosophila NDPK is known as 
AWD. AWD was detected in extracellular vesicles released from Drosophila cell lines [22]. Although 
the function of AWD released in this way remains to be determined, it has also been detected in vivo 
in the haemolymph which serves as the Drosophila transport system for other important molecules 
including  nutrients, hormones, defence molecules and mediators of responses to wounding [23].  
Similarly the human NDPK, Nm23-H1, can be detected in the blood. Nm23-H1 is one of 10 human 
NDPKs and until recently has perhaps been the most studied. Interest in Nm23-H1 and its closely 
related Nm23-H2 was given great impetus by observations by Patricia Steeg and colleagues that 
these proteins are suppressors of cancer metastasis [24-26]. Elevated Nm23-H1 expression is 
inversely correlated with metastatic potential in experimental rodent cell cancer models and in 
human tumours such as breast, ovarian, cervical, bladder, pancreatic and gastric cancer, 
hepatocellular carcinoma and melanomas [27]. In these settings, overexpression predicts a 
favourable patient outcome [26-33]. In these tumours, Nm23-H1 accumulates intracellularly as 
demonstrated using immunohistochemistry [27]. There is also some data that show human breast, 
colon, pancreas and lung cancer cells have Nm23-H1 and –H2 at their cell surface [34, 35] and can 
secrete it into the culture media in vitro [34, 36, 37]. In addition, laboratory studies in breast cancer 
suggest that the Nm23 secreted by breast cancer cells may influence breast cancer growth and 
metastasis [37, 38]. However, studies need to be done to confirm these observations and activities 
in patients. In contrast, elevated serum levels of Nm23-H1 have been reported in several 
haematological malignancies [39, 40]. In acute myeloid leukaemia (AML), peripheral T cell lymphoma 
[41], diffuse large B cell lymphoma (DLBCL) [42], and in Hodgkin lymphoma [43] elevated serum 
Nm23-H1 positively correlates with disease stage and is a negative prognostic factor for response to 
treatment  [44-46]. This is also the case for neuroblastoma [47].   
The role of extracellular Nm23-H1 in haematological malignancies 
The elevated levels of Nm23-H1 found in the serum of AML patients or other haematological 
malignancies may merely reflect the tumour cell origin of the protein. In this scenario, the 
association of higher levels with poorer prognosis may merely be a surrogate measure of tumour 
load, which itself is a negative prognostic indicator in these settings. The alternative model, that 
elevated extracellular Nm23-H1 levels are a driver of disease activity, required evidence in the same 
way that eNPDKs have been mechanistically implicated in M. tuberculosis, P. gingivalis and L. 
amazonensis infections. 
In this regard a seminal study by Okabe-Kado et al showed that recombinant extracellular Nm23-H1, 
applied at concentrations commensurate with those that corresponded to poorest prognosis, 
promoted the survival of cultured human primary AML cells. They further demonstrated that 
enhanced survival of AML cells in response to Nm23-H1 was associated with secretion of cytokines 
including IL-1β, TNF-α and activation of MAPK and STAT signalling pathways [48]. In a complimentary 
study, Lilly et al went on to show that the pro-survival effect of Nm23-H1 on AML blast cells was 
indirect [49]. Nm23-H1 produced and secreted by AML blast cells bound to more mature 
monocytoid components of the tumour clone, eliciting production of inflammation associated 
cytokines, which were able to promote survival and proliferation of the AML blast cells [40]. Lilly et 
al did not measure TNF-α, but did observe both IL-1βb and IL-6 amongst a number of cytokines. 
Importantly, the combined treatment of AML cells with IL-1β and IL-6 was able to replicate the 
indirect actions of Nm23-H1 on AML cells [49]. In a subsequent study, IL-1βb and IL-6 were shown to 
activate NFκB signalling and Tyr-705 phosphorylation of STAT3 respectively in KG1a AML cells [40]; 
indicating that activation of STAT signalling observed by Okabe-Kado et al is likely to be an indirect 
consequence of Nm23-H1.   Taken together, the data from these independent laboratories strongly 
implicate extracellular Nm23-H1 in the biology and progression of AML and as a therapeutic target 
[39, 40]. As yet, studies investigating the biological significance of elevated Nm23-H1 in the lymphoid 
haematological malignancies are lacking. 
The actions of extracellular Nm23-H1 are not just restricted to malignant haematological cells [50]. 
Willems et al demonstrated that Nm23-H1 (and also Nm23-H2 and -H3), whilst not modulating cell 
proliferation, were able to alter terminal differentiation of normal haemopoietic stem/progenitor 
cells promoting erythroid differentiation and suppressing macrophage colonies [51]. In a separate 
study, immobilised recombinant Nm23-H1 was able to modulate in vitro neurite outgrowth from 
embryonic chick dorsal root ganglia in a concentration dependant manner [52]. In fact, in the 
presence of high concentrations of Nm23-H1, neurites preferentially grew on Nm23-H1 substrate 
and turned away from other permissive coatings such as collagen.  
Exogenously added Nm23-H1 was also demonstrated to enable serial passage of human embryonic 
stem (ES) cells and induced pluripotent stem (iPS) cells in the absence of feeder cells or exogenously 
added growth factors [53, 54]. The Nm23-H1 treated ES and iPS cells maintained pluripotency during 
the experiments. These studies highlighted the potential of Nm23-H1 as a mechanism for expanding 
ES and iPS cells. 
How do NDPKs exit cells? 
Whilst there is now convincing evidence for the role of eNDPK in the infection settings and also in 
cancers, the mechanisms by which they are secreted has not been fully elucidated [7]. In the case of 
eNDPKs derived from intracellular pathogens, the proteins have to transverse the barriers of the 
bacterium envelope and cell wall and the host cell plasma membrane. These mechanisms have yet 
to be fully elucidated.  
Chakrabarty et al demonstrated that NDPK, whilst being intracellular in both mucoid and non-
mucoid P. aeruginosa, was also selectively secreted by mucoid P. aeruginosa by a type 1 secretion 
system [11] and that this secretion was mediated by DXXX motifs in the NDPK carboxy terminus [12]. 
However, it has been argued that these residues may not fulfil the specified requirements [15].  
The secretion of P. gingivalis NDPK from gingival epithelial cells was demonstrated to be mediated 
through interactions with the hemichannel pannexin 1 (PNX1) and the motor molecule myosin 9 
[10]. Furthermore, several studies have described interactions between NDPKs and Dynamin, a 
family of GTPAses involved in membrane-remodelling events e.g. endocytosis and receptor 
trafficking in drosophila [55-58], Dictyostelium discoideum [59], C.elegans [60] and human models 
[61-64]. Some of these studies imply that dynamin may mediate the secretion/export of Nm23-H1 
from cells. However, the data is not definitive and further work needs doing in this area.  
How do host and pathogen derived eNDPKs communicate with human cells; the case for the NLRP3 
inflammasome 
Extracellular nucleotides and nucleosides, especially eATP, mediate diverse signalling effects in 
virtually all organs and tissues impacting upon inflammatory signalling and immune responses 
especially during infections [41]. Purinergic signalling occurs via a series of nucleotide-selective 
ligand-gated P2X, metabotropic P2Y and P2Z receptors on macrophages as well as adenosine 
receptors which are present on many immune cells and also cancers [41, 42]. Purinergic signalling 
depends upon the levels of extracellular nucleotides/nucleosides which are regulated by (i) the 
release of endogenous ATP and other nucleotides, and (ii) enzymatic interconversion of nucleosides 
and nucleotides by extracellular kinases. It is therefore attractive to propose that this is the major 
route via which eNPDKs can influence host responses. 
As discussed above, purinergic signalling can be seen as a unifying paradigm across M. tuberculosis, 
P. gingivalis and L. amazonensis infections. In the case of P. Gingivalis, it seems likely that NDPK 
released from host cells and its modulation of eATP reduced reactive oxygen species (ROS) levels 
and diminished NLRP3 inflammasome activation, resulting in the suppression of secretion of the pro-
inflammatory cytokine IL1-β from infected cells and immune cells [32, 33]. This contrasts with the 
studies in AML where exposure of cells to Nm23-H1 clearly drove IL1-β secretion [49, 65] which is a 
marker widely recognised as a surrogate for NLRP3 inflammasome activation rather than 
suppression. 
In other studies, Dar et al demonstrated that NDPK secreted from intracellular pathogens Salmonella 
typhimurium and Mycobacterium typhimurium and the extracellular pathogen Vibrio cholerae were 
able to prevent eATP-induced cytolysis of J774 macrophage cells [8]. In contrast, Mycobacterium 
tuberculosis secreted NDPK enhanced ATP-induced macrophage cell death [66]. Interestingly, the 
kinase activity of M. tuberculosis NDPK was required for this activity which was mediated through 
the P2Z receptor [66]. This was also the case for Pseudomonas aeruginosa NDPK which was 
demonstrated to be secreted from bacteria, together with other ATP utilising enzymes, and elicited 
strong cytotoxic effects against murine peritoneal primary macrophages in the presence of eATP 
[67]. Thus, NDPKs appear to promote survival or enhance cell death of immune cells in response to 
eATP in different contexts. 
The canonical NLRP3 inflammasome pathway in macrophages results in characteristic cytolysis 
termed pyroptosis, a form of cell death characterised by cell swelling and plasma membrane rupture 
[68]. However, more recently non-canonical/alternative NLRP3 inflammasome pathways have been 
shown to induce secretion of IL-1β from human monocytes in the absence of cell death [69, 70]. 
Thus, as has been described, the rescue from cell death in response to eATP mediated by NDPKs 
from M. tuberculosis, P. Gingivalis, S. typhimurium, M. typhimurium, V. cholerae and L. amazonensis 
is consistent with suppression of the canonical NLRP3 inflammasome pathway in macrophages (or in 
the case of P. gingivalis gingival epithelial cells). In contrast, the Nm23-H1 stimulated IL1-β release 
from AML patient monocytes in the absence of cell death is more consistent with activation of non-
canonical/alternative NLRP3 inflammasome pathways.  
At present the promoted cell death of macrophages by M. tuberculosis and P. aeruginosa NDPKs is 
difficult to interpret in the context of NLRP3 inflammasome signalling unless they activate canonical 
inflammasome pathways independently of regulating eATP pools. At present this is difficult to 
reconcile with the observations given that the kinase activity of M. tuberculosis NDPK was required 
for its cell death promoting activity which was also mediated through the P2Z receptor for eATP [66].  
It is important to note that not all the actions of eNDPKs appear to be dependent on kinase activity 
since the redirected differentiation of haemopoietic stem/progenitor cells and directed outgrowth 
of neurites from chick embryo dorsal root ganglia were recapitulated by Nm23-H1 H118F mutant 
recombinant proteins that lack kinase activity [52]. 
Is there a surface receptor for NDPKs on human cells? 
A number of observations have identified Nm23-H1 at the surface of human cells indicating the 
possibility of surface receptors [34, 35, 40]. Interestingly, both the studies of Okabe-Kado et al and 
Lilly et al identified that not all primary AML samples respond to exogenously added Nm23-H1  [39, 
40]. In the study by Lilly et al, commercial antibodies to Nm23-H1 and flow cytometry identified that 
~50 % of primary AML samples contained mononuclear cells that stained positive for Nm23-H1 at 
their surface at the point of harvest and that these samples corresponded to those AMLs that 
respond to exogenous Nm23-H1 in vitro [49]. The addition of exogenous recombinant Nm23-H1 
then increased staining intensity on these positive samples as measured by flow cytometry [49]. The 
fact that not all samples contain cells that bound Nm23-H1, either at harvest or after exposure to 
Nm23-H1 in culture, suggests that the observed binding is not non-specific implying the presence of 
a selectively expressed receptor. However, this receptor is currently unknown.  
Studies by Bamdad and colleagues have identified a cleaved form of the transmembrane receptor 
MUC1, that they have termed MUC1*, as the putative cell surface receptor for Nm23-H1. These 
studies were performed predominantly on ES and iPS cells [53, 71]. These observations are 
potentially important since Nm23-H1 activity may be utilised to propagate large numbers of 
pluripotent stem cells for therapeutic interventions and urgently need corroborating in independent 
studies. Importantly, an early study from the Bamdad group identified that cross linking of MUC1* 
activated MAP kinase signalling cascade and stimulated cell growth [54]. Although this study did not 
utilise Nm23-H1 to cross link MUC1*, the observation resonates with Nm23-H1 mediated MAPK 
activation in AML as observed by Okabe-Kado et al [65].  However as we have discussed previously 
the data of Lilly et al indicate that MUC1* is not the Nm23-H1 cell surface receptor in AML [40, 49]. 
 
Concluding remarks  
As is always the case, the ‘known-knowns’ of eNDPKs discussed herein highlight a number of 
‘known–unknowns’ (Figure 1). The first of these is how the proteins are translocated from within 
prokaryotic and eukaryotic cells to their extracellular environments. Although the cumulative 
evidence is now that this occurs without cell damage, the mechanisms remain very poorly defined 
(Figure 1). It is possible that a common mechanism occurs across bacteria but equally it is reasonable 
to assume aspects of the process will vary between gram positive and gram negative organisms. For 
example, Spooner and Yilmaz have postulated a role for outer membrane vesicle transport of NDPKs 
from gram negative bacteria [15].  Equally, the process could differ between extracellular and 
intracellular pathogens. In the case of intracellular pathogen NPDKs, it is reasonable to consider that 
the export from their host cell utilises the same mechanism that cell may use for its own NDKP 
export. However, the mechanism(s) by which this occurs remain poorly defined. 
Once released, it is as yet uncertain whether intercellular communication via eNDPK occurs 
exclusively locally, as implied in the case of regulation of host cell activation via eATP, or whether 
systemic communication at long distances and across different cell and tissue types occurs. 
Related to this issue is the ‘known-unknown’ regarding potential receptors for eNDPKs. Again, in the 
case of regulating eATP levels, a receptor for NDPK is not required but rather the presence of 
receptors that perceive ATP or related molecules. Nonetheless, the studies in AML suggest that 
NDPK must bind to the cell surface to mediate its effect suggesting that a receptor is likely to exist. 
Such a receptor may then be also important in local eATP if it is required to tether NDPK to the cell 
surface in order to intimately regulate pericellular eATP concentrations. As described above, a 
candidate receptor is MUC1* but this has yet to be corroborated independently and at least one 
study suggests it is not the receptor in AML. Are there therefore multiple mammalian NDPK surface 
receptors? 
Another concept that has yet to be explored is whether the export systems for NDPKs are reversible 
or whether surface bound NDPKs can be internalised. If so, NDPKs could have intracellular actions in 
cells not of their origin, making the opportunities for cell-cell, tissue-tissue and organ-organ 
communication still greater than currently being discussed. 
The studies we have referred to herein have largely focused on human pathogens and human 
disease processes that have informed our as yet limited understanding of the functions and 
importance of signalling via eNDPKs. As we have highlighted, the roles of NDPKs in the biology of 
environmental prokaryotes is a yet to be explored space. For example, can prokaryotes exploit 
NDPKs for quorum sensing or impacting upon the behaviours of other species, both prokaryotic and 
eukaryotic in their environment? Finally, in this review we have disregarded functions of NDPKs in 
plants. This is an emerging field that requires further investigation. As has been the case for non-
plant eukaryotic organisms,  the early focus has been on intracellular actions of NDPKs [72] but it is 
reasonable to also predict extracellular roles for NDPKs in Planta. 
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Figure 1: The known-knowns and known-unknowns of extracellular NDPK proteins 
 The figure summarises the key points discussed in the review and highlights some of what is known 
about how NDPKs are exported from prokaryotic and eukaryotic cells, and some of the functions of 
extracellular NDPKs. The left side schematically represents what we know about prokaryotic NDPKs 
and the right hand panel is a summary of eukaryotic NDPKs. Prokaryotic NDPKs are shown either as 
tetramers or as hexamers to reflect the variability between prokaryotes whereas the vast majority of 
eukaryotic NDPK are hexameric. Solid arrows denote actions/mechanisms which have been 
observed experimentally and published in the literature. Dashed arrows indicate 
pathways/mechanisms for which there is currently little/no evidence. P2X7R, P2YR and P2ZR are 
purinergic receptors. Abbreviations: OMV-Outer membrane vesicle, ROS- reactive oxygen species. 
 

